Dr. med. Christian Waldherr | Röntgeninstitut Brunnhof | Bern | Schweiz

FMH Diagnostische Radiologie
FMH Nuklearmedizin


Zeitsoldat, Leutnant d.R. Deutschland 1988 – 1990
Rettungssanitäter, DRK-SH, Deutschland 1990
Humanmedizin Universität Würzburg, Deutschland 1991 – 1994
Humanmedizin Universität Kiel, Deutschland 1994 – 1998


Assistenzarzt, Institut für Nuklearmedizin, Universität Basel 1998 – 2002
Forschungsassistent (Nationalfonds-Stipendium) Biological Imaging Center,
University of California, Los Angeles, USA 2002 – 2003
Assistenzarzt, Institut für Diagnostische Radiologie, Universität Bern 2003 – 2007
Oberarzt, Institut für Diagnostische Radiologie, Universität Bern 2007 – 2009

Oberarzt Radiologengruppe Brunnhof 2009 – 2014

  • Röntgeninstitut Brunnhof, Bern
  • Radiologie und Nuklearmedizin Klinik Engeried, Bern
  • Radiologie Klinik Sonnenhof, Bern
  • MR-Diagnostik, Thun


Oberarzt Radiologie, Schwerpunkt Mammadiagnostik und MSK
Oberarzt Nuklearmedizin, Schwerpunkt Allgemeine Nuklearmedizin

Gesellschafter Radiologengruppe Brunnhof 2014 bis heute

  • Röntgeninstitut Brunnhof, Bern
  • Radiologie und Nuklearmedizin Klinik Engeried, Bern
  • Radiologie Klinik Sonnenhof, Bern
  • MR-Diagnostik Thun


Leiter Nuklearmedizin Klinik Engeried, Bern 2014 bis heute
Stv Leiter Radiologie und Nuklearmedizin Klinik Engeried, Bern 2014 bis heute
Leiter Nuklearmedizin Röntgeninstitut Brunnhof, Bern 2017 bis heute

Seit 2018:

Vorstandsmitglied der Ärztevertretung der Lindenhofspitäler

Beirat (international advisory board) Brustzentrum Zypern, Nikosia, Republik Zypern




Atlas of Breast Tomosynthesis
Martin Sonnenschein, Christian Waldherr, Springer Verlag, veröffentlicht 26. Juni 2017


Publikationen (Peer reviewed)

  1. Tomosynthesis-guided vacuum-assisted breast biopsy: A feasibility study.
    Waldherr C, Berclaz G, Altermatt HJ, Cerny P, Keller P, Dietz U, Buser K, Ciriolo M, Sonnenschein MJ. Eur Radiol. 2016 Jun;26(6):1582-9. Epub 2015 Sep 18.
  1. Value of one-view breast tomosynthesis versus two-view mammography in diagnostic workup of women with clinical signs and symptoms and in women recalled from screening.
    Waldherr C, Cerny P, Altermatt HJ, Berclaz G, Ciriolo M, Buser K, Sonnenschein MJ. AJR Am J Roentgenol. 2013 Jan;200(1):226-31. doi: 10.2214/AJR.11.8202.
  1. MR imaging of parotid tumors: typical lesion characteristics in MR imaging improve discrimination between benign and malignant disease.
    Christe A, Waldherr C, Hallett R, Zbaeren P, Thoeny H. AJNR Am J Neuroradiol. 2011 Aug;32(7):1202-7. doi: 10.3174/ajnr.A2520. Epub 2011 Jun 30.
  1. MR motility imaging in Crohn’s disease improves lesion detection compared with standard MR imaging.
    Froehlich JM, Waldherr C, Stoupis C, Erturk SM, Patak MA. Eur Radiol. 2010 Aug;20(8):1945-51. doi: 10.1007/s00330-010-1759-x. Epub 2010 Apr 9.
  1. Interventional management of hypervascular osseous metastasis: role of embolotherapy before orthopedic tumor resection and bone stabilization.
    Kickuth R, Waldherr C, Hoppe H, Bonel HM, Ludwig K, Beck M, Triller J. AJR Am J Roentgenol. 2008 Dec;191(6):W240-7. doi: 10.2214/AJR.07.4037.
  1. Intra- and retroperitoneal irrigation liquid after arthroscopy of the hip joint.
    Haupt U, Völkle D, Waldherr C, Beck M. Arthroscopy. 2008 Aug;24(8):966-8. doi: 10.1016/j.arthro.2007.02.019. Epub 2007 Oct 3.
  1. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
    Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Anticancer Res. 2006 Jan-Feb;26(1B):703-7.
  1. Superselective embolization of deep femoral artery branch pseudoaneurysm with a coaxial microcatheter system.
    Waldherr C, Kickuth R, Ludwig K, Do DD, Triller J. Vasa. 2006 Feb;35(1):45-9.
  1. Adductor insertion avulsion syndrome, „thigh splints“: relevance of radiological follow-up.
    Tshering-Vogel D, Waldherr C, Schindera ST, Steinbach LS, Stauffer E, Anderson SE. Skeletal Radiol. 2005 Jun;34(6):355-8. Epub 2004 Oct 2.
  1. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET.
    Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J, Phelps ME, Silverman DH, Sawyers CL, Czernin J. J Nucl Med. 2005 Jan;46(1):114-20.
  1. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
    Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, Maecke HR. Cancer Res. 2004 Sep 15;64(18):6707-15.
  1. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
    Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J. Lung Cancer. 2004 Sep;45(3):365-71.
  1. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
    Forrer F, Uusijärvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke HR. Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1257-62. Epub 2004 Jun 10.
  1. Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. A Case Report.
    Meier G, Waldherr C, Herrmann R, Maecke H, Mueller-Brand J, Pless M. Oncology. 2004;66(2):160-3.
  1. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability.
    Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, Ratib O, Czernin J. J Nucl Med. 2004 May;45(5):797-801.
  1. Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images.
    Halpern BS, Dahlbom M, Waldherr C, Yap CS, Schiepers C, Silverman DH, Ratib O, Czernin J. J Nucl Med. 2004 Feb;45(2):290-3.
  1. Cigarette smoking and coronary blood flow.
    Czernin J, Waldherr C. Prog Cardiovasc Dis. 2003 Mar-Apr;45(5):395-404. Review.
  1. Angioleiomyoma: nuclear medical-radiologic diagnosis of a rare soft tissue tumor.
    Waldherr Ch, Tabacek G, Suess K, Müller-Brand J. Nuklearmedizin. 2002 Oct;41(5):N62-4. German. No abstract available.
  2. Kidney failure after treatment with 90Y-DOTATOC.
    Schumacher T, Waldherr C, Mueller-Brand J, Maecke H. Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):435. No abstract available.
  1. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
    Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. J Nucl Med. 2002 May;43(5):610-6.
  1. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
    Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. Ann Oncol. 2001 Jul;12(7):941-5.
  1. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
    Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, Haldemann A, Mueller-Brand J. Nucl Med Commun. 2001 Jun;22(6):673-8.
  1. Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
    Waldherr C, Haldemann A, Maecke HR, Crazzolara A, Mueller-Brand J. Clin Oncol (R Coll Radiol). 2000;12(2):121-3.
  1. Ga-67 scintigraphy in a patient with B-cell lymphoma.
    Waldherr C, Otte A, Mueller-Brand J. Clin Nucl Med. 2000 May;25(5):389. No abstract available.
  1. Marine-Lenhart syndrome: a case observation upon 18 years.
    Waldherr C, Otte A, Haldemann A, Müller-Brand J. Nuklearmedizin. 1999;38(8):345-8. German.